Eaton Vance Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $10.8M | Buy |
88,079
+1,429
| +2% | +$188K | 0.02% | 573 |
|
|
2022
Q2 | $11.5M | Buy |
86,650
+1,742
| +2% | +$237K | 0.02% | 580 |
|
|
2022
Q1 | $11.6M | Buy |
84,908
+65,347
| +334% | +$9.11M | 0.01% | 650 |
|
|
2021
Q4 | $3.38M | Buy |
19,561
+1,427
| +8% | +$217K | ﹤0.01% | 888 |
|
|
2021
Q3 | $2.38M | Sell |
18,134
-863
| -5% | -$126K | ﹤0.01% | 900 |
|
|
2021
Q2 | $2.51M | Buy |
18,997
+1,609
| +9% | +$211K | ﹤0.01% | 959 |
|
|
2021
Q1 | $2.23M | Buy |
17,388
+607
| +4% | +$74.8K | ﹤0.01% | 948 |
|
|
2020
Q4 | $2M | Buy |
16,781
+13
| +0.1% | +$1.58K | ﹤0.01% | 926 |
|
|
2020
Q3 | $1.92M | Sell |
16,768
-131
| -0.8% | -$15.5K | ﹤0.01% | 847 |
|
|
2020
Q2 | $1.93M | Sell |
16,899
-24
| -0.1% | -$2.55K | ﹤0.01% | 824 |
|
|
2020
Q1 | $1.36M | Buy |
16,923
+1,459
| +9% | +$151K | ﹤0.01% | 838 |
|
|
2019
Q4 | $1.65M | Sell |
15,464
-237
| -2% | -$24.7K | ﹤0.01% | 873 |
|
|
2019
Q3 | $1.68M | Sell |
15,701
-178
| -1% | -$18.3K | ﹤0.01% | 844 |
|
|
2019
Q2 | $1.62M | Buy |
15,879
+64
| +0.4% | +$6.15K | ﹤0.01% | 846 |
|
|
2019
Q1 | $1.42M | Buy |
15,815
+237
| +2% | +$20.5K | ﹤0.01% | 840 |
|
|
2018
Q4 | $1.3M | Sell |
15,578
-300
| -2% | -$28.1K | ﹤0.01% | 810 |
|
|
2018
Q3 | $1.71M | Hold |
15,878
| – | – | ﹤0.01% | 796 |
|
|
2018
Q2 | $1.75M | Sell |
15,878
-578
| -4% | -$60.2K | ﹤0.01% | 766 |
|
|
2018
Q1 | $1.65M | Buy |
16,456
+250
| +2% | +$25.6K | ﹤0.01% | 729 |
|
|
2017
Q4 | $1.6M | Sell |
16,206
-300
| -2% | -$28.4K | ﹤0.01% | 740 |
|
|
2017
Q3 | $1.55M | Sell |
16,506
-509
| -3% | -$54K | ﹤0.01% | 737 |
|
|
2017
Q2 | $1.89M | Buy |
17,015
+500
| +3% | +$52.9K | 0.01% | 694 |
|
|
2017
Q1 | $1.62M | Sell |
16,515
-100
| -0.6% | -$9.53K | ﹤0.01% | 681 |
|
|
2016
Q4 | $1.53M | Sell |
16,615
-100
| -0.6% | -$8.62K | ﹤0.01% | 649 |
|
|
2016
Q3 | $1.42M | Sell |
16,715
-475
| -3% | -$39.9K | ﹤0.01% | 644 |
|
|
2016
Q2 | $1.4M | Sell |
17,190
-4,928
| -22% | -$375K | ﹤0.01% | 629 |
|
|
2016
Q1 | $1.58M | Sell |
22,118
-3,197
| -13% | -$214K | ﹤0.01% | 596 |
|
|
2015
Q4 | $1.8M | Hold |
25,315
| – | – | 0.01% | 581 |
|
|
2015
Q3 | $1.56M | Hold |
25,315
| – | – | ﹤0.01% | 602 |
|
|
2015
Q2 | $1.84M | Hold |
25,315
| – | – | 0.01% | 547 |
|
|
2015
Q1 | $1.95M | Hold |
25,315
| – | – | 0.01% | 563 |
|
|
2014
Q4 | $1.7M | Hold |
25,315
| – | – | 0.01% | 576 |
|
|
2014
Q3 | $1.54M | Sell |
25,315
-1,000
| -4% | -$61.6K | ﹤0.01% | 568 |
|
|
2014
Q2 | $1.54M | Sell |
26,315
-2,100
| -7% | -$123K | ﹤0.01% | 584 |
|
|
2014
Q1 | $1.65M | Sell |
28,415
-8,810
| -24% | -$472K | ﹤0.01% | 570 |
|
|
2013
Q4 | $1.99M | Sell |
37,225
-1,200
| -3% | -$71.2K | 0.01% | 530 |
|
|
2013
Q3 | $2.37M | Sell |
38,425
-2,500
| -6% | -$150K | 0.01% | 471 |
|
|
2013
Q2 | $2.48M | Buy |
+40,925
| New | +$2.44M | 0.01% | 452 |
|
Other funds holding DGX
Eaton Vance Management's DGX Position: Q3 2022 in Review
Eaton Vance Management increased its Quest Diagnostics (DGX) stake by 1.6% in Q3 2022, buying an estimated $188K and bringing the position to 88,079 shares worth $10.8M. The position accounts for 0.02% of the portfolio, ranked #573.
Eaton Vance Management first reported a position in DGX in Q2 2013 and has held it in 38 quarters since. The position peaked at $11.6M in Q1 2022. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.
- Eaton Vance Management held 88,079 shares of Quest Diagnostics worth $10.8M as of Q3 2022.
- Eaton Vance Management bought 1,429 Quest Diagnostics shares in Q3 2022, an estimated $188K.
- Quest Diagnostics made up 0.02% of Eaton Vance Management's portfolio in Q3 2022, its #573 holding.
- Eaton Vance Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Quest Diagnostics position peaked at $11.6M in Q1 2022.
- 808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.